Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China

• DOI: 10.1007/s11596-021-2326-1
• Publication Date: 2021-02-14T09:25:44Z
• Authors: Xiao-na Chang; Fu-mei Shang; Hong-yu Jiang; Chen Chen; Zhe-yan Zhao; Sheng-he Deng; Jun Fan; Xiao-chuan Dong; Ming Yang; Yan Li; Kai-lin Cai; Li Liu; Hong-li Liu; Xiu Nie
• Keywords: Adult; Male; Proto-Oncogene Proteins B-raf; Membrane Proteins; Middle Aged; Survival Analysis; GTP Phosphohydrolases; 3. Good health; Proto-Oncogene Proteins p21(ras); 03 medical and health sciences; 0302 clinical medicine; Predictive Value of Tests; Lymphatic Metastasis; Mutation; Biomarkers, Tumor; Humans; Female; Colorectal Neoplasms; Aged

The incidence of colorectal cancer (CRC) is increasing in China, with high mortality. Here, we aimed to evaluate the latest clinicopathological features and prognostic value of the KRAS/NRAS/BRAF mutation status in CRC patients in Central China. The clinical data of 1549 CRC patients with stage I-IV disease diagnosed at Union Hospital, Tongji Medical College of Huazhong University of Science and Technology from 2015 to 2017 were collected and analyzed retrospectively. KRAS/NRAS/BRAF mutations were detected by real-time quantitative polymerase chain reaction (q-PCR) in 410 CRC patients, with mutation frequencies of KRAS, NRAS and BRAF of 47.56%, 2.93% and 4.15%, respectively. The gene mutation status and clinicopathological characteristics of 410 patients with CRC who underwent qPCR were analyzed. The KRAS and BRAF gene mutations were related to the pathological differentiation and number of metastatic lymph nodes. The BRAF gene mutation was also associated with cancer thrombosis in blood vessels. Cox regression analysis showed that there was no statistically significant difference in the overall survival (OS) between patients with KRAS, NRAS mutants and wild-type CRC patients, while the BRAF gene mutation was negatively correlated with the OS rate of CRC patients. It is suggested that the BRAF gene mutation may be an independent risk factor for the prognosis of CRC.